Reber Genetics is committed to developing innovative and high-quality animal vaccines and applying human cancer immunotherapy to the treatment of animal diseases
In 2012, through patented technologies such as "reverse genetic engineering technology" and "target cell-specific fusion antigen", we successfully developed the first vaccine product for pigs - Porcine Reproductive and Respiratory Syndrome Subunit Vaccine (PRRSFREE), which brought human immunotherapy into the veterinary field and was the first of its kind in the animal husbandry industry.
The original traditional vaccines (live virus vaccines or inactivated vaccines) have limitations in their use. With the advancement of the biotechnology industry, the main development trend of new vaccines is to break through the limitations of the original traditional vaccines through the improvement of biotechnology and the introduction of genetic engineering, with vaccines with high safety and high economic efficiency as the main development direction. Reber Genetics introduced animal vaccine research through genetic engineering technology and successfully developed a new type of "sub-unit vaccine"greatly improving the safety of vaccines.
‧PRRSFREE is the world's first subunit vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) successfully developed by Reber Genetics
Due to the safety and effectiveness of the vaccine, the vaccination rate of PRRS vaccine in Taiwan has gradually increased, and sales in domestic and foreign markets have grown steadily. Later, in 2019, it successfully developed the new subunit vaccine CIRCOQ for porcine circular virus infection, obtained a manufacturing license and officially launched it in Taiwan. Sales performance in Taiwan has also increased year by year.‧Taiwan’s first PICS/GMP compliant animal vaccine company
Reber Genetics has undergone corporate transformation in the direction of developing high-value, high-safety animal vaccine products. It has also actively upgraded the software and hardware equipment of the original factory and strengthened professional training for employees. In 2021, the Guanyin factory successfully passed the EU PICS/GMP We strictly follow factory inspection standards and become the first animal vaccine company in Taiwan that complies with PICS/GMP.‧Seek technical cooperation with industry, academia and industry with an open attitude
It uses a diversified business model to develop domestic and foreign markets. At the same time, Ruibao has an excellent sales team and strong distribution channels, as well as factory equipment that meets PICS/GMP specifications. It can produce high-quality products that meet international standards and hopes to move towards a leading brand of animal vaccines in the future.
Innovative research and development & the pursuit of high-quality products are the main business purposes